Cibus (CBUS)
NASDAQ:CBUS
Want to see CBUS full AI Analyst Report?
CBUS Stock Chart & Stats
$1.59
-$0.23(-7.99%)
At close: 4:00 PM EST
$1.59
-$0.23(-7.99%)
Day’s Range― - ―
52-Week Range$1.09 - $4.19
Previous CloseN/A
Volume64.89K
Average Volume (3M)154.04K
Market Cap
$103.81M
Enterprise Value$304.50M
Total Cash (Recent Filing)$30.32M
Total Debt (Recent Filing)$276.15M
Price to Earnings (P/E)―
Beta2.80
Next Earnings
Aug 06, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding76,331,635
10 Day Avg. Volume164,630
30 Day Avg. Volume154,044
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)36.47
Price to Sales (P/S)218.79
P/FCF Ratio-15.56
Enterprise Value/Market Cap2.93
Enterprise Value/Revenue71.05
Enterprise Value/Gross Profit98.58
Enterprise Value/Ebitda-4.89
Forecast
1Y Price Target
$14.00Price Target Upside780.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.19
Revenue Forecast (FY)$7.78M
Bulls Say, Bears Say
Bulls Say
Extended Runway / Capital RaiseThe ~ $37M gross capital raise and $30.3M cash balance materially extend operating runway into late Q1 2027, providing durable near‑term financing that buys time to execute commercial pilots, secure partner payoffs, and reduce reliance on immediate dilutive financings while pursuing regulatory approvals.
Meaningful Cost ReductionsSustained cuts in R&D and SG&A have materially narrowed quarterly losses and target annual net cash usage to ~ $30M, improving structural cash flow dynamics. Lower fixed overhead increases the odds of getting to breakeven with less incremental capital, enhancing financial flexibility over the medium term.
Regulatory MomentumMultiple positive APHIS determinations and equivalence findings in Ecuador/Peru materially reduce regulatory barriers across key markets. This structural clarity lowers commercialization risk, accelerates partner deployment prospects, and supports recurring royalty potential as trait approvals are confirmed.
Bears Say
Heavy Cash BurnPersistent ~-$50M TTM operating and free cash flow versus a small revenue base creates a lasting financing imperative. High absolute burn means recurring capital needs, raises dilution risk, and constrains long‑term investment choices unless revenues or margins materially improve.
Early-stage Partnerships / LOIsMany commercial arrangements are non‑binding LOIs or partner‑funded development, leaving revenue visibility weak. Durable commercialization depends on partners converting LOIs to definitive deals and executing launches; failures or delays would materially reduce projected royalties and cash inflows.
Third‑party Regulatory / Chemical DependenciesThe U.S. rollout is gated by an external herbicide registration timetable outside company control. Such dependencies create structural timing and execution risk: delayed partner approvals compress royalty windows, defer revenue, and can force additional financing or reduce projected returns from core trait launches.
Cibus News
CBUS FAQ
What was Cibus’s price range in the past 12 months?
Cibus lowest stock price was $1.09 and its highest was $4.19 in the past 12 months.
What is Cibus’s market cap?
Cibus’s market cap is $103.81M.
When is Cibus’s upcoming earnings report date?
Cibus’s upcoming earnings report date is Aug 06, 2026 which is in 46 days.
How were Cibus’s earnings last quarter?
Cibus released its earnings results on May 14, 2026. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.27 by -$0.06.
Is Cibus overvalued?
According to Wall Street analysts Cibus’s price is currently Undervalued.
Does Cibus pay dividends?
Cibus does not currently pay dividends.
What is Cibus’s EPS estimate?
Cibus’s EPS estimate is -0.27.
How many shares outstanding does Cibus have?
Cibus has 76,331,635 shares outstanding.
What happened to Cibus’s price movement after its last earnings report?
Cibus reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.27. Following the earnings report the stock price went down -7.092%.
Which hedge fund is a major shareholder of Cibus?
Currently, no hedge funds are holding shares in CBUS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cibus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (780.50% Upside)
$14.00 (780.50% Upside)
Hedge Fund Trend
Decreased
By 22.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.92%
12-Months-Change
Fundamentals
Return on Equity
-225.59%
Trailing 12-Months
Asset Growth
-3.24%
Trailing 12-Months
Company Description
Cibus
Cibus, Inc. is an agricultural technology company dedicated to innovating and commercializing advanced plant characteristics. The firm's business model involves creating these beneficial traits and then licensing them to seed producers, generating revenue through royalty payments. Cibus primarily concentrates its efforts on two key areas: 1. Boosting Farm Productivity: This involves developing traits that enable farmers to achieve greater crop yields while simultaneously minimizing their need for synthetic crop protection agents and fertilizers. 2. Pioneering Sustainable Components: The company also engineers environmentally responsible ingredient alternatives, offering corporations solutions to replace materials derived from fossil fuels or those whose manufacturing processes significantly contribute to greenhouse gas emissions. The company's headquarters are located in San Diego, California.
CBUS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized execution: material commercial progress in LATAM rice (LOI, import permit, delivery of edited materials), clear technical advances (order-of-magnitude improvement in editing efficiency; wheat single-cell regeneration), regulatory tailwinds, and tangible cost reductions that materially improved the P&L and extended runway after raising ~ $37M gross. Offsets include a limited cash runway into Q1 2027 absent stronger near-term revenue, a U.S. rice launch delay from 2028 to 2029 due to herbicide registration timing, continued sizable quarterly net losses and interest on royalty liabilities, and several commercial arrangements still at LOI or early stages. Overall, the positives (capital raise, execution on priority programs, technical and regulatory momentum, and meaningful expense reductions) outweigh the negatives, though the company's trajectory remains execution-dependent.View all CBUS earnings summariesCBUS Stock 12 Month Forecast
Average Price Target
$14.00
▲(780.50% Upside)
Technical Analysis
Ownership Overview
25.66% Insiders
8.57% Mutual Funds
5.25% Other Institutional Investors
57.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---